Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Evolus Inc (NQ: EOLS )

11.47 -0.23 (-1.97%)
Streaming Delayed Price Updated: 11:17 AM EDT, Apr 24, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 46,583
Open 11.68
Bid (Size) 11.47 (4)
Ask (Size) 11.49 (4)
Prev. Close 11.70
Today's Range 11.40 - 11.68
52wk Range 7.070 - 15.43
Shares Outstanding 54,576,156
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Evolus to Report First Quarter Financial Results on May 7, 2024
From Evolus
Via Business Wire
Evolus Announces Publication of Safety and Duration Data from Phase 2 Study for “Extra-Strength” 40U Formulation of Jeuveau®
From Evolus
Via Business Wire

Performance

YTD
+14.81%
+14.81%
1 Month
-16.88%
-16.88%
3 Month
-2.38%
-2.38%
6 Month
+44.46%
+44.46%
1 Year
+31.69%
+31.69%

More News

Read More
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Evolus
Via Business Wire
Recap: Evolus Q4 Earnings
Via Benzinga
Earnings Outlook For Evolus
Via Benzinga
Evolus to Participate in the 23rd Annual Needham Virtual Healthcare Conference
From Evolus
Via Business Wire
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Evolus Announces Pricing of $50.0 Million Underwritten Offering of Common Stock
From Evolus
Via Business Wire
AbbVie Stock Clears Key Benchmark, Hitting 80-Plus RS Rating
Via Investor's Business Daily
Evolus Inc. (NASDAQ: EOLS) Leading the Way in Wednesday Trading Based on Percentage Gain
Via Investor Brand Network
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Evolus
Via Business Wire
EOLS Stock Earnings: Evolus Misses EPS, Beats Revenue for Q4 2023
Via InvestorPlace
Evolus Reports Record Fourth Quarter and Full Year 2023 Financial Results; Reaffirms 2024 Guidance
From Evolus
Via Business Wire
Evolus Announces Results from European Head-to-Head Filler Trial
From Evolus
Via Business Wire
Earnings Scheduled For March 7, 2024
Via Benzinga
Evolus to Participate in Upcoming Leerink Partners and Barclays Investor Conferences
From Evolus
Via Business Wire
Evolus to Report Fourth Quarter and Year End 2023 Results and Provide Business Update on March 7, 2024
From Evolus
Via Business Wire
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Evolus
Via Business Wire
Novo Nordisk Stock Just Earned A 92 RS Rating; Gapped Up On Earnings
Via Investor's Business Daily
Why Panbela Therapeutics Shares Are Trading Lower By 65%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
SoFi Technologies Posts Q4 Earnings, Joins Cardlytics, McGrath RentCorp And Other Big Stocks Moving Higher On Monday
Via Benzinga
Topics Stocks
Exposures US Equities
Evolus Set For Promising 2024: Analysts Maintain Positive Outlook On Botox Alternative Maker
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Evolus Announces Preliminary Unaudited Fourth Quarter and Full-Year 2023 Net Revenue, Achieving Record Results and Exceeding Expectations; Issues 2024 Guidance
From Evolus
Via Business Wire
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Evolus
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.